(SRRK) Scholar Rock Holding - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.677m USD | Total Return: 58% in 12m
Avg Turnover: 54.7M
Warnings
Interest Coverage Ratio -54.3 is critical
Altman Z'' -14.38 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the development of monoclonal antibodies. The company utilizes a proprietary technology platform to target the latent forms of growth factors within the TGFβ superfamily, aiming to treat neuromuscular diseases, cancer, and fibrosis.
The company’s primary clinical asset, apitegromab, is an inhibitor of myostatin activation currently undergoing trials for spinal muscular atrophy (SMA). Its broader pipeline includes SRK-439 for neuromuscular disorders and SRK-181, which targets solid tumors resistant to existing immunotherapy treatments. In the biotechnology sector, companies focusing on rare diseases often benefit from regulatory incentives such as Orphan Drug Designation, which can provide extended market exclusivity upon approval.
The business model relies on the high-risk, high-reward nature of drug discovery, where significant capital is deployed into research and development prior to achieving commercial revenue. For a deeper look into the companys valuation metrics and financial health, consider reviewing the latest data on ValueRay. This scientific approach to protein activation allows Scholar Rock to target specific isoforms, potentially reducing off-target effects compared to traditional systemic inhibitors.
- Apitegromab Phase 3 clinical trial results determine primary valuation for SMA treatment
- Regulatory approval timelines for myostatin inhibitors dictate near-term commercial revenue potential
- Expansion into obesity and cardiometabolic markets drives long-term investor sentiment
- Cash burn rate and financing needs impact share price through potential dilution
- Success of TGF beta platform in solid tumors influences pipeline diversification value
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.65 > 0.02 and ΔFCF/TA -10.32 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -303.5m > Net Income -408.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.3m) vs 12m ago 13.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -54.30 > 6 (EBITDA TTM -398.9m / Interest Expense TTM 7.38m) |
| A: 0.85 (Total Current Assets 515.3m - Total Current Liabilities 59.6m) / Total Assets 535.3m |
| B: -2.63 (Retained Earnings -1.41b / Total Assets 535.3m) |
| C: -0.85 (EBIT TTM -400.5m / Avg Total Assets 471.4m) |
| D: -5.42 (Book Value of Equity -1.41b / Total Liabilities 259.2m) |
| Altman-Z'' = -14.38 = D |
As of May 24, 2026, the stock is trading at USD 47.72 with a total of 1,031,138 shares traded.
Over the past week, the price has changed by -2.47%,
over one month by +1.69%,
over three months by +2.38% and
over the past year by +58.01%.
Scholar Rock Holding has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy SRRK.
- StrongBuy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 59 | 23.6% |
P/B = 20.5696
Revenue TTM = 0.0 USD
EBIT TTM = -400.5m USD
EBITDA TTM = -398.9m USD
Long Term Debt = 99.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 6.08m USD (from shortTermDebt, last quarter)
Debt = 214.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.21m
Net Debt = -265.1m USD (calculated: Debt 214.9m - CCE 479.9m)
Enterprise Value = 5.41b USD (5.68b + Debt 214.9m - CCE 479.9m)
Interest Coverage Ratio = -54.30 (Ebit TTM -400.5m / Interest Expense TTM 7.38m)
EV/FCF = -15.67x (Enterprise Value 5.41b / FCF TTM -345.3m)
FCF Yield = -6.38% (FCF TTM -345.3m / Enterprise Value 5.41b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.60m) / Revenue TTM)
Tobins Q-Ratio = 10.11 (Enterprise Value 5.41b / Total Assets 535.3m)
Interest Expense / Debt = 3.43% (Interest Expense 7.38m / Debt 214.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -316.4m (EBIT -400.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.48 (Total Current Assets 515.3m / Total Current Liabilities 68.9m)
Debt / Equity = 0.78 (Debt 214.9m / totalStockholderEquity, last quarter 276.0m)
Debt / EBITDA = 0.66 (negative EBITDA) (Net Debt -265.1m / EBITDA -398.9m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -265.1m / FCF TTM -345.3m)
Total Stockholder Equity = 249.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -86.70% (Net Income -408.7m / Total Assets 535.3m)
RoE = -24.68% (Net Income TTM -408.7m / Total Stockholder Equity 1.66b)
RoCE = -22.81% (EBIT -400.5m / Capital Employed (Equity 1.66b + L.T.Debt 99.7m))
RoIC = -84.94% (negative operating profit) (NOPAT -316.4m / Invested Capital 372.5m)
WACC = 11.14% (E(5.68b)/V(5.89b) * Re(11.46%) + D(214.9m)/V(5.89b) * Rd(3.43%) * (1-Tc(0.21)))
Discount Rate = 11.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 25.77%
[DCF] Fair Price = unknown (Cash Flow -345.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.55 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.84 | Chg30d=+0.06% | Revisions=+0% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-0.86 | Chg30d=+0.45% | Revisions=-14% | Analysts=14
EPS current Year (2026-12-31): EPS=-3.10 | Chg30d=-2.62% | Revisions=-9% | GrowthEPS=+5.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.55 | Chg30d=-9.16% | Revisions=-43% | GrowthEPS=+19.7% | GrowthRev=+2195.3%
[Analyst] Revisions Ratio: -43%